A Business Analysis of Amgen, Inc

Paper Summary:

The paper describes the activities of Amgen, Inc., which markets a range of drugs using recombinant engineering techniques. This paper provides a business analysis of this company, including an overview of Amgen and its product line, the macro-environment in which the company competes, a political, social and environmental factor analysis, and a review of relevant economic factors that can be be reasonably expected to affect the company in the future. A review of Amgen's track record concerning its mission, goals and ethics is followed by an analysis of its corporate level and business unit strategies. Finally, the paper provides an analysis of Amgen's various financial data and performances compared to its competitors, followed by a summary of the research and salient recommendations in the conclusion.

Outline:
Introduction
Review and Discussion
Company Overview
Macro-environment
Political, Social and Environmental Factors
Economic Factors
Technology Factors
Industry Environment .
Resources, Mission, Goals, and Ethics
Corporate Level Strategies
Profit and Loss Account
Business Unit Strategies
Financial Ratios
Valuation Measures
Financial Highlights
Conclusion and Recommendations

From the Paper:

"In addition, the company is involved with a joint venture with Kirin Brewery Company, Limited, for the development and commercialization of products based on advanced biotechnology, as well as a co-promotion agreement with industry leader Wyeth concerning the manufacture, supply, inventory, and allocation of bulk supplies of Enbrel (Amgen, 2007). Amgen is also collaborating with Cytokinetics, Inc. in an effort to discover, develop, and commercialize unique small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure (Amgen, 2007). The company's headquarters remain in Thousand Oaks, California (Amgen, 2007)."

Sample of Sources Used:

• Amgen. (2007). Yahoo! Finance. [Online]. Available: http://finance.yahoo.com/q/pr?s=AMGN.
• Anderson, W. P., & Breznitz, S. M. (2005). Boston Metropolitan Area biotechnology cluster. Canadian Journal of Regional Science, 28(2), 2.
• Brownlee, S. (2004, March). Plunder drugs: Why Americans believe they have to put up with pharmaceutical profiteering. Washington Monthly, 36(3), 55.
• Collins, S. W. (2004). The race to commercialize biotechnology: Molecules, markets, and the state in the United States and Japan. New York: RoutledgeCurzon.
• Dennick, R., & Exley, K. (2004). Small group teaching. New York: RoutledgeFalmer.

More papers on A Business Analysis of Amgen, Inc:

• Analytical Essay # 3987 : "A Financial Analysis of Boeing Inc."
• Analytical Essay # 116097 : "Financial Analysis of Nutrisystem Inc."
• Analytical Essay # 147895 : "A Self Analysis of Conflict Resolution Behavior"

APA Citation:

MLA Citation: